The estimated Net Worth of Mark Daniels is at least $13.5 Millón dollars as of 31 March 2021. Mr. Daniels owns over 1,167 units of Twist Bioscience Corp stock worth over $3,020,605 and over the last 6 years he sold TWST stock worth over $9,792,101. In addition, he makes $703,972 as Senior Vice President, Chief Legal Officer y Chief Ethics and Compliance Officer and Secretary at Twist Bioscience Corp.
Sign up
Mr. Daniels TWST stock SEC Form 4 insiders trading
Mark has made over 20 trades of the Twist Bioscience Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,167 units of TWST stock worth $31,112 on 31 March 2021.
The largest trade he's ever made was selling 70,475 units of Twist Bioscience Corp stock on 15 December 2020 worth over $9,349,918. On average, Mark trades about 4,573 units every 18 days since 2018. As of 31 March 2021 he still owns at least 68,093 units of Twist Bioscience Corp stock.
You can see the complete history of Mr. Daniels stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Daniels biography
Mark Daniels J.D. serves as Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary of the Company. Prior to joining us, from January 2013 to May 2016, Mr. Daniels was at Broadcom Corporation, a semiconductor manufacturer and producer of wireless and broadband products, where his most recent position was Vice President, Law and Deputy Chief Corporate Compliance Officer. Before that, he spent 20 years in positions of increasing responsibility in the legal department at Amgen, Inc., a producer of biopharmaceuticals, where his last role was Vice President and Associate General Counsel. Mr. Daniels received his B.S. with honors in Industrial and Labor Relations from Cornell University and a J.D., cum laude, from Harvard Law School.
What is the salary of Mark Daniels?
As the Senior Vice President, Chief Legal Officer y Chief Ethics and Compliance Officer and Secretary of Twist Bioscience Corp, the total compensation of Mark Daniels at Twist Bioscience Corp is $703,972. There are 7 executives at Twist Bioscience Corp getting paid more, with Emily Leproust having the highest compensation of $8,126,160.
How old is Mark Daniels?
Mark Daniels is 57, he's been the Senior Vice President, Chief Legal Officer y Chief Ethics and Compliance Officer and Secretary of Twist Bioscience Corp since 2018. There are 9 older and 13 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
What's Mark Daniels's mailing address?
Mark's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Twist Bioscience Corp
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell y Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
What does Twist Bioscience Corp do?
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
What does Twist Bioscience Corp's logo look like?
Complete history of Mr. Daniels stock trades at Twist Bioscience Corp
Twist Bioscience Corp executives and stock owners
Twist Bioscience Corp executives and other stock owners filed with the SEC include:
-
Emily Leproust,
Chairman of the Board, President, Chief Executive Officer -
James Thorburn,
Chief Financial Officer -
Patrick Finn,
Chief Commercial Officer -
Dr. Emily Marine Leproust Ph.D.,
Co-Founder, Chairman, Pres & CEO -
Patrick Weiss,
Chief Operating Officer -
James M. Thorburn,
Chief Financial Officer -
Dr. Patrick John Finn Ph.D.,
Chief Commercial Officer -
Mark Daniels,
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary -
Dr. William Charles Banyai Ph.D.,
Sr. VP of Advanced Devel., GM of Data Storage & Director -
Jan Johannessen,
Independent Director -
Nelson Chan,
Independent Director -
Robert Ragusa,
Independent Director -
Keith Crandell,
Independent Director -
Robert Chess,
Lead Independent Director -
Xiaoying Mai,
Independent Director -
Nicolas Barthelemy,
Independent Director -
William Banyai,
Director -
Paula Green,
Vice President of Human Resources -
Bill Peck,
Chief Technology Officer -
Erin Smith,
Senior Vice President - Government affairs and Public policy -
Martin Kunz,
Senior Vice President - Operation -
Patrick Weiss,
Chief Operating Officer -
Tracey Mullen M.B.A.,
Sr. VP of Operations -
Paula Green,
Sr. VP of HR -
Dennis Cho,
Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer -
Kevin B. Yankton,
VP & Chief Accounting Officer -
Mark Daniels Esq.,
Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. -
Dr. Aaron K. Sato,
Chief Scientific Officer & Chief Scientific Officer of BioPharma -
Siyuan Chen,
Chief Technology Officer -
Adam Laponis,
Chief Financial Officer -
Alpha Fund L.P. Ever,
10% owner -
Fred B Craves,
Director -
Venture Partners Viii, Llca...,
-
Melissa A. Starovasnik,
-
Dennis Cho,
See Remarks -
Kevin Bruce Yankton,
Chief Accounting Officer -
Robert F. Werner,
Chief Accounting Officer